61Cu-NODAGA-PSMA

N/A

Report date: 2025/09/15 17:59:59

NME

Base Information

Drug Name61Cu-NODAGA-PSMA

Drug Alias Name61Cu-NODAGA-PSMA

ClassificationRadiation-emitting products > Radioactive diagnostic agentSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Copper > 61Cu +[4]

Mechanisms of ActionPositron-emission tomography enhancersTransient receptor potential cation channel subfamily V member 4 modulators

TargetsTransient receptor potential cation channel subfamily V member 4

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesHoag Memorial Hospital Presbyterian

China Registration ClassN/A

Develop Information

Active CompaniesHoag Memorial Hospital Presbyterian

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A